Generic Isentress Availability
Last updated on Oct 9, 2024.
See also: Generic Isentress HD
Isentress is a brand name of raltegravir, approved by the FDA in the following formulation(s):
ISENTRESS (raltegravir potassium - powder;oral)
-
Manufacturer: MSD SUB MERCK
Approval date: December 20, 2013
Strength(s): EQ 100MG BASE/PACKET [RLD]
ISENTRESS (raltegravir potassium - tablet, chewable;oral)
-
Manufacturer: MSD SUB MERCK
Approval date: December 21, 2011
Strength(s): EQ 25MG BASE [RLD], EQ 100MG BASE [RLD]
ISENTRESS (raltegravir potassium - tablet;oral)
-
Manufacturer: MSD SUB MERCK
Approval date: October 12, 2007
Strength(s): EQ 400MG BASE [RLD]
Has a generic version of Isentress been approved?
No. There is currently no therapeutically equivalent version of Isentress available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isentress. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7169780*PED
Patent expiration dates:
- April 3, 2024✓
- April 3, 2024
-
Patent 7,754,731
Patent expiration dates:
- March 11, 2029✓✓✓
- March 11, 2029
-
Patent 7754731*PED
Patent expiration dates:
- September 11, 2029✓
- September 11, 2029
-
Pharmaceutical composition containing an anti-nucleating agent
Patent 8,771,733
Issued: July 8, 2014
Inventor(s): Cruanes Maria T. & Xu Wei & Artino Laura M. & Zhu Honggang
Assignee(s): Merck Sharp & Dohme Corp.Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.
Patent expiration dates:
- June 2, 2030✓✓✓
- June 2, 2030
-
Pharmaceutical formulation containing a release rate controlling composition
Patent 8,852,632
Issued: October 7, 2014
Inventor(s): Pourkavoos Nazaneen & Ney James R. & Cruanes Maria T. & Wu Yunhui & Palkar Saurabh A.
Assignee(s): Merck Sharp & Dohme Corp.Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R, R, Rand Rare defined herein. The formulations are suitable for use in the inhibition of HIV integrase, the treatment and prophylaxis of HIV infection, and the treatment, prophylaxis and delay in the onset of AIDS.
Patent expiration dates:
- January 28, 2028✓✓✓
- January 28, 2028
More about Isentress (raltegravir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (17)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: integrase strand transfer inhibitor
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
